FinkleWD, GreenlandS, RidgewayGK, et al.Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLOS ONE, 2014; 9:e85805.
3.
U.S. Department of Health and Human Services, U.S. Food and Drug Administration. Safety Announcement. FDA evaluating risk of stroke, heart attack and death with FDA-approved testosterone products. January31, 2014. Available at www.fda.gov/drugs/drugsafety/ucm383904.htm Last accessed February24, 2014.
4.
ShoresMM, SmithNL, ForsbergCW, et al.Testosterone treatment and mortality in men with low testosterone levels. J Clin Endocrinol Metab, 2012; 97:2050–2058.
5.
MuraleedharanV, MarshH, KapoorD, et al.Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. Eur J Endocrinol, 2013; 169:725–733.
6.
AversaA, BruzzichesR, FrancomanoD, et al.Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: Results from a 24-month, randomized, double-blind, placebo-controlled study. J Sex Med, 2010; 7:3495–3503.
7.
EnglishKM, SteedsRP, JonesTH, DiverMJ, ChannerKS. Low dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina – a randomized, double-blind, placebo-controlled study. Circulation, 2000; 102:1906–1911.
CoronaG, RastrelliG, MonamiM, et al.Hypogonadism as a risk factor for cardiovascular mortality in men: A meta-analytic study. Eur J Endocrinol, 2011; 165:687–701.
